March 12, 2012
Patients in Pakistan suffering from iron deficiency
anaemia gain access to treatment with Monofer®.
Monofer® (iron isomaltoside 1000) is introduced in Pakistan and is
now available for patients suffering from iron deficiency.
Monofer® is indicated for the treatment of absolute or functional
iron deficiency when oral iron preparations are ineffective or
cannot be used and when there is a clinical need to deliver iron
"With the introduction of Monofer®, we are now able to meet a
large medical need for a broad range of patients in Pakistan
suffering from iron deficiency, hereunder pregnant women where iron
deficiency prevalence is high," says Kennet Brysting, VP Sales
& Marketing at Pharmacosmos.
On a global scale, WHO estimates that more than 2 billion people
suffer from anaemia, mainly due to iron deficiency.
Monofer® is marketed by Pharmacosmos' partner in Pakistan, AllMed
Monofer® is an innovative intravenous (i.v.) iron
replacement therapy discovered and developed by Pharmacosmos A/S.
Iron isomaltoside 1000 is the active pharmaceutical ingredient of
To date, Monofer® has gained marketing authorisation in 23
countries worldwide and been introduced in the United Kingdom,
Ireland, Denmark, Sweden, Norway, Poland, Finland, the Netherlands,
Germany and Pakistan.
In many countries, intravenous iron replacement products are
primarily used to treat dialysis patients. However, iron deficiency
anaemia is often a complication of many other illnesses and
Pharmacosmos conducts research in different therapeutic areas such
as chronic kidney disease (CKD), oncology (chemotherapy induced
anaemia), cardiology (chronic heart failure), gynaecology (heavy
uterine bleeding) and gastroenterology (inflammatory bowel
About Pharmacosmos A/S
Pharmacosmos develops and markets
medicines for the treatment of iron deficiency. A research-based
company, its ongoing R&D programme focuses on improving the
treatment options for healthcare professionals, patients suffering
from iron deficiency and veterinary treatments. .
Pharmacosmos is a family-owned
Danish company and operates in more than 50 countries across
Europe, the Americas and Asia. Its facilities are approved by both
the Danish Medicines Agency and the US Food & Drug